Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Treatment-Resistant Depression in Autism
NCT06731621Phase 1Active, not recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by Center for Addiction and Mental Health. Primary endpoints: Feasibility of Administering Psilocybin in Conjunction with Psychotherapy at 12 weeks, Subjective Psychedelic Effects as Measured by the 11-Dimensions of Altered States of Consciousness Rating Scale at 2 weeks and 2 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06731621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731621.